Outcomes by Tumor Histology and KRAS Mutation Status After Lung Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Outcomes by Tumor Histology and KRAS Mutation Status After Lung Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Published:2015-01 Issue:1 Volume:16 Page:24-32
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Mak Raymond H.,Hermann Gretchen,Lewis John H.,Aerts Hugo J.W.L.,Baldini Elizabeth H.,Chen Aileen B.,Colson Yolonda L.,Hacker Fred H.,Kozono David,Wee Jon O.,Chen Yu-Hui,Catalano Paul J.,Wong Kwok-Kin,Sher David J.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference22 articles.

1. Outcome in a prospective phase II trial of medically inoperable stage I non–small-cell lung cancer patients treated with stereotactic body radiotherapy;Baumann;J Clin Oncol,2009

2. Stereotactic body radiation therapy for inoperable early stage lung cancer;Timmerman;JAMA,2010

3. Stereotactic body radiation therapy for early-stage non–small-cell lung carcinoma: four-year results of a prospective phase II study;Fakiris;Int J Radiat Oncol Biol Phys,2009

4. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study;Onishi;Cancer,2004

5. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non–small-cell lung cancer;Grills;J Clin Oncol,2011

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Role of Lymphocyte CD44 in Determining Treatment Selection Between Stereotactic Body Radiation Therapy and Surgery for Early-Stage Non-Small Cell Lung Cancer;International Journal of Radiation Oncology*Biology*Physics;2024-09

2. BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo;Cell Communication and Signaling;2024-06-13

3. Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles;Molecular Therapy - Nucleic Acids;2023-09

4. A PI3K gene expression signature predicts for recurrence in early‐stage non–small cell lung cancer treated with stereotactic body radiation therapy;Cancer;2023-08-10

5. Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology;Seminars in Radiation Oncology;2023-07